CellChorus

Life exists in motion. CellChorus® provides a high-throughput platform for evaluating how individual cells move, behave and interact.

[CellChorus @CellChorus]

Attending SITC 2024? Four abstracts from CellChorus and collaborators feature TIMING data! Join us to learn how dynamic single-cell analysis improves screening donors, enhancing ADCC, quantifying potency/viability, and more.
https://t.co/u5Ay8e37u2

@sitcancer

[CellChorus @CellChorus]

@EricTopol For example, here's an example of a T cell exhibiting trogocytosis
https://t.co/2xsOMdvapG

[CellChorus @CellChorus]

@EricTopol @EricTopol if you like videos of immune cells and tumor cells, you will love our channel here:
https://t.co/gEIT47J4oI

[Chuck Schumer @SenSchumer]

Trump’s decision to halt federal virtually all federal grants and loans is lawless, destructive, dangerous, and cruel.

It is illegal.

It is unconstitutional.

It’s nothing less than Project 2025 by another name.

Congress must act.

[InnovationMap @InnoMapHou]

CellChorus announced that the company, along with The University of Houston, has been awarded up to $2.5 million in funding. https://t.co/q3ekbLPHoT

[GenomeWeb @GenomeWeb]

In Brief This Week: Bruker, Qiagen, Prenetics, CellChorus, T2 Biosystems, More https://t.co/Hegn9s1shM

[Breakout Ventures @breakout_vc]

Attending #SITC24 this week?Be sure to check out the 𝒇𝒐𝒖𝒓 presentations featuring data from @CellChorus' single-cell analysis technology! https://t.co/uP8kFYfpMD

[CellChorus @CellChorus]

Congrats to @sunilacharya13, @lab_rezvani & collaborators for publishing in Cancer Discovery how CD28 costimulation enhances CAR-NK cell function! CAR27 NK cells with CD28-based costimulation were ~3x more likely to exhibit serial killing. Learn more:
https://t.co/Gf1J3F5P5S

[CellChorus @CellChorus]

💥 @CellChorus and @UHouston received a $2.5 million STTR fast-track award for innovations in AI/ML from the @ncats_nih_gov at @NIH. Learn more:

https://t.co/hgnuIM4t2t

#ai #artificialIntelligence #ml #machineLearning #singleCell #singleCellAnalysis @UHEngineering

[CellChorus @CellChorus]

Want to learn how to apply TIMING™ for potency and viability analysis in process development? Meet with us at BioProcess International in Boston Sept 25th + 26th.

Already registered? Book a meeting in the conference app:
https://t.co/3qEXcQXGNi

@BioProcessIntl @InformaConnect

[CellChorus @CellChorus]

- TIMING measurements of cell movements during target engagement (synapse) showed that Hy-CAR-Ts maintained significantly more motility than donor-matched Nuc-CAR-T cells. Motility has been linked to strong CAR-T potency and patient response in other studies.

[CellChorus @CellChorus]

🚨 @IndeeLabs posted a manuscript that applies TIMING™ data from @CellChorus to show that CAR-T cells manufactured with the Indee platform have superior motility and resistance to activation-induced cell death (AICD).

https://t.co/KX25PzCaFe

@RBerdeaux @MohsenFathi1993

[CellChorus @CellChorus]

- TIMING data showed that individual Hy-CAR-T target seeking. contact dynamics, and target killing were just as robust as Nuc-CAR-T. ‍

- TIMING data showed that Hy-CAR-T were more resistant to activation-induced cell death (AICD) AICD contributes to exhaustion of CAR-T cells.

[Y Combinator @ycombinator]

Immunotherapy is a powerful tool in fighting cancer, but not all patients respond.

However, a team of cancer researchers has recently discovered a new subset of T cells with the @CELLCHORUS (S21) TIMING platform that could improve outcomes for patients: https://t.co/CBDbYePiFQ

[Nature Cancer @NatureCancer]

Check out the latest articles @NatureCancer "Identification of a clinically efficacious CAR T cell subset in diffuse large B cell lymphoma by dynamic multidimensional single-cell profiling" https://t.co/45CYXfCjDA

[UH Media Relations @UH_News]

Team of #cancer researchers, led by @UHouston, discovered new #Tcells that may improve outcome for patients treated with T-cell therapies, especially those suffering from #lymphoma.
#lymphoma https://t.co/Epi6bf9F12